EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

Papaverine safety during pregnancy: Insights from a large population‐based cohort of pregnancies

Yael Levi iD, Tal Michael, Saar Dor iD, Gali Pariente, Eitan Lunenfeld, Amalia Levy, Shira Birenstock-Choen, Sharon Daniel iD

British Journal of Clinical Pharmacology · 2025-06 · 91 (6) · 1780-1789

DOI: 10.1111/bcp.16404 ↗

At a glance

Journal article in British Journal of Clinical Pharmacology, published online on 2025-02-06. Written by Yael Levi and 7 co-authors. Institution: Department of Epidemiology, Biostatistics, and Community Health Sciences, School of Public Health, Ben-Gurion University of the Negev, Beer-Sheva, Is…. Major MEDLINE topics: Papaverine, Abnormalities, Drug-Induced, Vasodilator Agents. Cited 4 times so far (Crossref); 33 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Aims

Papaverine hydrochloride functions as an antispasmodic and vasodilator medication. Data concerning the teratogenic risk of papaverine is currently lacking. The aims of this paper are to examine the association between first‐trimester exposure to papaverine and major congenital malformations and the association between third trimester exposure to papaverine and late adverse pregnancy outcomes.

Methods

We conducted a population‐based retrospective cohort study that included pregnant women 15–49 years old insured by ‘Clalit Health Services’ in southern Israel, who gave birth or had an elective pregnancy termination due to suspected fetal malformation at Soroka Medical Center between 1999 and 2017. Multivariate negative binomial regression models were used to examine the associations between papaverine during the first trimester and major congenital malformations, and between papaverine during the third trimester and late adverse pregnancy outcomes, adjusting for potential confounders.

Results

The study included a total of 254 333 pregnancies, of which 3604 (1.41%) were exposed to papaverine during the first trimester, and 1253 (0.49%) during the third trimester. No significant associations were found between first‐trimester exposure to papaverine and total congenital major malformations or specific malformations according to organ systems in the multivariate analysis (adjusted RR for: total major malformations = 1.021; 95% confidence interval (CI) [0.895–1.165], cardiovascular = 1.073; 95% CI [0.905–1.273], central nervous system = 0.784; 95% CI [0.484–1.271], musculoskeletal = 0.823; 95% CI [0.588–1.153], gastrointestinal = 0.887; 95% CI [0.457–1.718], genitourinary = 1.076; 95% CI [0.805–1.438]). Additionally, we did not detect significant associations between third‐trimester exposure to papaverine and late adverse pregnancy outcomes.

Conclusions

Exposure to papaverine during pregnancy was not associated with adverse pregnancy outcomes in the population studied, compared with non‐exposed pregnancies.

Subjects

MeSH terms (MEDLINE)

PapaverineAbnormalities, Drug-InducedVasodilator AgentsHumansFemalePregnancyAdultRetrospective StudiesAdolescentIsraelYoung AdultPregnancy Trimester, FirstMiddle AgedPregnancy OutcomePregnancy Trimester, Third

Author keywords

adverse outcomescongenital malformationspapaverinepregnancyteratogenic risk

Substances

PapaverineVasodilator Agents

Authors and institutions

  • Department of Epidemiology, Biostatistics, and Community Health Sciences, School of Public Health, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Department of Obstetrics and Gynecology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Adelson School of Medicine, Ariel University, Ariel, Israel.
  • Department of Social Services, Soroka University Medical Center, Beer-Sheva, Israel.
  • Department of Pediatrics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Clalit Health Services, Southern District, Beer-Sheva, Israel.

ORCID profiles: Yael Levi, Saar Dor, Sharon Daniel

Cite

APA

Levi, Y., Michael, T., Dor, S., Pariente, G., Lunenfeld, E., Levy, A., Birenstock-Choen, S., & Daniel, S. (2025). Papaverine safety during pregnancy: Insights from a large population‐based cohort of pregnancies. British Journal of Clinical Pharmacology, 91(6), 1780-1789. https://doi.org/10.1111/bcp.16404

Vancouver

Levi Y, Michael T, Dor S, Pariente G, Lunenfeld E, Levy A, et al. Papaverine safety during pregnancy: Insights from a large population‐based cohort of pregnancies. British Journal of Clinical Pharmacology. 2025;91(6):1780-1789. doi:10.1111/bcp.16404

BibTeX
@article{Levi2025,
  author = {Levi, Yael and Michael, Tal and Dor, Saar and Pariente, Gali and Lunenfeld, Eitan and Levy, Amalia and Birenstock-Choen, Shira and Daniel, Sharon},
  title = {Papaverine safety during pregnancy: Insights from a large population‐based cohort of pregnancies},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  volume = {91},
  number = {6},
  pages = {1780--1789},
  doi = {10.1111/bcp.16404}
}
Start for free →